tetano
Editor, Senior Moderator
Immun Inflamm Dis
. 2024 May;12(5):e1273.
doi: 10.1002/iid3.1273. Effect of increasing doses of colchicine on the treatment of 333 COVID-19 inpatients
Rumen Tiholov[SUP] 1 [/SUP], Aleksander I Lilov[SUP] 2 [/SUP], Gergana Georgieva[SUP] 3 [/SUP], Kiril R Palaveev[SUP] 2 [/SUP], Konstantin Tashkov[SUP] 4 [/SUP], Vanyo Mitev[SUP] 5 [/SUP]
Affiliations
Background: Previous research done in Bulgaria demonstrated a fivefold reduction in mortality from COVID-19 with increased doses of colchicine from two hospitals in the country. We report here a further 333 cases of COVID-19 inpatients, treated with different doses of colchicine and its effect on mortality.
Materials and methods: A case-control comparison from two additional hospitals was conducted between increased doses of colchicine and added bromhexine to standard of care (SOC) versus current SOC. Risk and odds ratio, as well as subgroup analysis, was conducted with newly reported data, alongside aggregate data from all hospital centers to determine the extent of mortality reduction in COVID-19 inpatients.
Results: There was a clear reduction in the mortality of inpatients with increasing doses of colchicine-between twofold and sevenfold. Colchicine loading doses of 4 mg are more effective than those with 2 mg. Despite these doses being higher than the so-called "standard doses," colchicine inpatients experienced lower mortality than SOC patients (5.7% vs. 19.53%). This mortality benefit was evident in different age subgroups, with a 4-mg loading dose of colchicine proving slightly superior to a 2-mg loading dose. Colchicine led to an overall relative risk reduction of 70.7%, with SOC patients having 3.91 higher odds of death. The safety of the doses was not different than the reported in the summary of product characteristics.
Conclusion: Inpatients in Bulgaria with added colchicine and bromhexine to SOC achieved better clinical and mortality outcomes than those on SOC alone. These results question the World Health Organization-recommended strategy to inhibit viral replication. We posit that our treatment strategy to inhibit the Severe acute respiratory syndrome coronavirus 2 entry into the cell with inhaled bromhexine and the hyperactivated NLRP3 inflammasome with higher doses of colchicine, prevents the development of cytokine storm. The timing of the initiation of treatment seems critical.
Keywords: COVID‐19 mortality; COVID‐19 treatment; NLRP3 inflammasome; colchicine; cytokine storm.
. 2024 May;12(5):e1273.
doi: 10.1002/iid3.1273. Effect of increasing doses of colchicine on the treatment of 333 COVID-19 inpatients
Rumen Tiholov[SUP] 1 [/SUP], Aleksander I Lilov[SUP] 2 [/SUP], Gergana Georgieva[SUP] 3 [/SUP], Kiril R Palaveev[SUP] 2 [/SUP], Konstantin Tashkov[SUP] 4 [/SUP], Vanyo Mitev[SUP] 5 [/SUP]
Affiliations
- PMID: 38798123
- DOI: 10.1002/iid3.1273
Background: Previous research done in Bulgaria demonstrated a fivefold reduction in mortality from COVID-19 with increased doses of colchicine from two hospitals in the country. We report here a further 333 cases of COVID-19 inpatients, treated with different doses of colchicine and its effect on mortality.
Materials and methods: A case-control comparison from two additional hospitals was conducted between increased doses of colchicine and added bromhexine to standard of care (SOC) versus current SOC. Risk and odds ratio, as well as subgroup analysis, was conducted with newly reported data, alongside aggregate data from all hospital centers to determine the extent of mortality reduction in COVID-19 inpatients.
Results: There was a clear reduction in the mortality of inpatients with increasing doses of colchicine-between twofold and sevenfold. Colchicine loading doses of 4 mg are more effective than those with 2 mg. Despite these doses being higher than the so-called "standard doses," colchicine inpatients experienced lower mortality than SOC patients (5.7% vs. 19.53%). This mortality benefit was evident in different age subgroups, with a 4-mg loading dose of colchicine proving slightly superior to a 2-mg loading dose. Colchicine led to an overall relative risk reduction of 70.7%, with SOC patients having 3.91 higher odds of death. The safety of the doses was not different than the reported in the summary of product characteristics.
Conclusion: Inpatients in Bulgaria with added colchicine and bromhexine to SOC achieved better clinical and mortality outcomes than those on SOC alone. These results question the World Health Organization-recommended strategy to inhibit viral replication. We posit that our treatment strategy to inhibit the Severe acute respiratory syndrome coronavirus 2 entry into the cell with inhaled bromhexine and the hyperactivated NLRP3 inflammasome with higher doses of colchicine, prevents the development of cytokine storm. The timing of the initiation of treatment seems critical.
Keywords: COVID‐19 mortality; COVID‐19 treatment; NLRP3 inflammasome; colchicine; cytokine storm.